He didn’t know it at the time, but when chemist Matthew Todd posted a request for help on The Synaptic Leap, a website devoted to open-source biomedical research, he was sowing the seeds for a rivalry between an open initiative and a contract-research organization hired by the World Health Organization to reach the same goal.
The aim of both projects, run in 2010, was to produce a safer, low-cost version of praziquantel, a treatment for the tropical parasitic infection schistosomiasis. Up until that point, the treatment contained two enantiomers (mirror-image versions of the molecule that have slightly different properties) of praziquantel. One enantiomer has no effect on the parasite, but gives the drug a bitter taste. Eliminating this undesirable form could reduce side effects and help more patients to complete their treatment. The pure drug needed to be affordable. Todd, who is at the University of Sydney in Australia, thought that an open project was the best way to achieve this. “Open is very well-suited for neglected diseases,” he says. “The pay-off of secrecy is not very large.” Continue reading
I reported and wrote an infographic on the epidemiology of liver cancer. It was a good growing experience to work with a designer and an editor on a piece of visual, data-oriented journalism. I learned a lot and ended up wanting to experiment more with conveying data visually, with words and stories as a complement, rather than the other way around. I’m looking forward to the next opportunity.
To best see the visual elements of the infographic, I recommend checking out the PDF below rather than the HTML web version.
First published by Nature Outlook: [html] [pdf].
For something that took years to arrive, Madrid’s public bicycles sure get off to a fast start. Pedal once and the 36-volt, 10-ampere, electric motors will give you a sudden boost. Going up one of Madrid’s many hills, it is a welcome aid. Downhill, the burst jars. But riders can disable the boost by not pedaling, and moderate it with electric controls on the handlebars. With a little practice, the bikes begin to feel like underpowered motor scooters. “Our major goal is to move journeys that are now done by car to the bicycles,” says Elisa Barahona, Madrid’s director of sustainability and environment.
In the middle of the evening rush hour last November 29 more than 1,000 London cyclists staged a “die-in” to protest the traffic deaths of fellow riders and to demand more investment in bike-friendly roads. London’s streets may have grown friendlier to cyclists since the 2010 introduction of its Barclays Cycle Hire bike-sharing system but according to those at the protest, London is still too dangerous. The hundreds of cities that have launched bicycle-sharing systems in the last decade offer similar reasons for doing it: Bicycling reduces car traffic and pollution in city centers and is healthy exercise. But although all road-users benefit from less-crowded streets, a recent study suggests that the health benefits of bike-sharing programs depend on who is doing the riding.London’s bike-sharing program had registered 191,702 users at last count. Public health researcher James Woodcock at the University of Cambridge in England and his colleagues imagined, and calculated, how those riders lives might have been different had they not used the bikes. They examined data from 2.1 million hours of use between April 2011 and March 2012 and compared the health impact of those 2.1 million hours with the alternatives: more walking, public transit use or driving. To their surprise, the team reports in the February 13 BMJ (British Medical Journal), the switch to cycling may not have been helpful for young women. The health benefits also seem to differ by age, with older riders of both genders gaining more benefits than younger ones.